<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095523</url>
  </required_header>
  <id_info>
    <org_study_id>100037</org_study_id>
    <secondary_id>10-C-0037</secondary_id>
    <nct_id>NCT01095523</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases</brief_title>
  <official_title>Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Survival rates for colorectal cancer depend on a number of factors, including the
           existence of tumors outside the colon and rectum. Patients who had tumors elsewhere in
           the abdomen (such as in the peritoneum or ovaries) when they were diagnosed, as well as
           patients who had bleeding or obstruction when they were diagnosed, have a high risk of
           cancer recurrence even after surgery or other treatment.

        -  If additional tumors are discovered early and removed while they are still small (often
           before they can show up on scans), survival rates may improve. In addition, patients who
           receive a heated chemotherapy solution delivered directly to the abdomen often have
           better treatment outcomes regardless of whether additional tumors were found. Further
           research can help determine the usefulness of both of these treatments in improving the
           outcomes of patients with colorectal cancer.

      Objectives:

      - To determine whether patients who have had surgery for colorectal cancer have improved
      outcomes after receiving additional surgery combined with direct chemotherapy, compared with
      those who receive the current standard of care.

      Eligibility:

      - Individuals at least 18 years of age who have had surgery for colorectal cancer within the
      past 14 months, who are considered to be at high risk for cancer recurrence, and whose
      current imaging scans show no signs of additional tumors.

      Design:

        -  Participants will be divided into two treatment groups: a surgery group and a standard
           of care group.

        -  Participants who had surgery less than 11 months ago will be enrolled in a 3-month
           lead-in phase to receive standard follow-up care, including labs, scans, and physical
           examinations, before being randomized to a treatment group between 11 and 14 months
           after surgery. Participants who had surgery between 11 and 14 months ago will be
           randomized at the time of enrollment.

        -  Participants in the surgery group will have the following procedures within 2 weeks of
           randomization:

        -  Abdominal surgery where surgeons will look for and remove any tumors and take biopsies
           to check for cancer cells

        -  Heated chemotherapy, with three chemotherapy drugs administered directly to the abdomen

        -  In-patient recovery and follow-up visits beginning 3 to 6 weeks after discharge.

        -  Participants in the standard of care group will have the standard follow-up schedule for
           high-risk colorectal cancer patients:

        -  Clinic evaluations every 3 months for 2 years, and then every 6 months for 3 years and
           yearly thereafter....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

        -  Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) treated with chemotherapy
           alone results in median survival of 5 to 13 months.

           .-Approximately, 55% of high risk patients (Patients presenting with synchronous PC,
           ovarian metastases perforated primary, and emergency presentation with bleeding or
           obstructing lesions) will develop PC.

        -  Early PC is undetectable by conventional imaging.

        -  Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for
           early PC from CRC resulted in median survival of 48-63 months and 5 year survival of 51
           %.

        -  This study is a prospective randomized trial designed to answer the question whether
           mandatory second look surgery (MSLS) with CRS and HIPEC will prolong overall survival
           when compared to the standard of care.

      OBJECTIVES:

      Primary Objective:

      - To compare the overall survival of patients at high risk for developing PC from CRC who
      undergo M SLS + HIPEC and CRS (if applicable) vs. similar patients who receive standard of
      care.

      Secondary Objectives:

        -  To determine recurrence-free survival in both arms.

        -  To investigate selection criteria for patient who might benefit from a strategy of MSLS
           with CRS + HIPEC.

      ELIGIBILITY:

        -  Patients who have undergone curative resection f or CRC who are at high risk for
           recurrence

        -  Patients who shown no evidence of disease at the time of enrollment

        -  Patients with ECOG less than or equal to 0-2 and suitable candidates for laparotomy,
           HIPEC and CRS.

      DESIGN:

        -  High risk CRC patients for developing PC who underwent curative surgery and subsequently
           received standard of care and remained NED for 12 months after primary surgery will be
           randomized into MSLS/CRS/HIPEC or continuing standard of care.

        -  HIPEC will be done using Oxaliplatin/5-FU/Leucovorin.

        -  Up to 100 patients will be enrolled to allow for 35 evaluable patients in each arm;
           accrual is expected to last 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 14, 2010</start_date>
  <completion_date type="Actual">February 9, 2012</completion_date>
  <primary_completion_date type="Actual">February 9, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.</measure>
    <time_frame>Follow-up will occur every 3 months for two years, every six months for three ye</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.</measure>
    <time_frame>Follow-up will occur every 3 months for two years, every six months for three ye</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparotomy+ HIPEC +/- CRS</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Histologically confirmed colorectal adenocarcinoma.

               2. Curative resection (NED at closure) for CRC which was (1) perforated into the
                  peritoneal cavity, (2) associated with minimal PC which was completely excised at
                  the time of initial operation, (3) T4 lesion that required en bloc resection of
                  additional organs, (4) associated with ovarian metastases or (5) emergency
                  presentation with lesions associated with obstruction and/or bleeding.

                  Note: Patient who presented at the time of diagnosis with limited extra abdominal
                  metastases may be eligible if the lesions were completely resected and the
                  patient remains NED.

               3. Received at least 3 months of standard of care adjuvant therapy and is disease
                  free by conventional imaging at time of registration and/or randomization.

                  Note: The imaging will be reviewed by an experienced radiologist and a surgical
                  attending prior to enrollment.

               4. Greater than or equal to 18 years of age.

               5. Must be able to understand and sign the Informed Consent

               6. Clinical performance status of ECOG less than or equal to 2.

               7. Life expectancy of greater than three months.

               8. Patients of both genders must be willing to practice birth control during and for
                  four months after receiving chemotherapy.

               9. Hematology:

          -  Absolute neutrophil count greater than 1500/mm(3) without the support of Filgrastim.

          -  Platelet count greater than 75,000/mm(3).

          -  Hemoglobin greater than 8.0 g/dl.

             j. Chemistry:

          -  Serum creatinine less than or equal to 1.5 mg/dl unless the measured creatinine
             clearance is greater than 60mL/min/1.73m(2).

          -  Total bilirubin less than or equal to 2 mg/dl, except for patients with diagnosis of
             Gilbert's disease or hepatic pedicle obstruction then total bilirubin must be less
             than or equal to 5 mg/dl.

             k. INR less than or equal to 1.8.

             l. Stable serum CEA levels

             m. No history of prior/other malignancies within the 2 years prior to enrollment with
             the exception of basal cell carcinoma.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breast feeding because of the
             potentially dangerous effects of the chemotherapy on the fetus or infant.

          2. Active systemic infections, coagulation disorders or other major medical illnesses
             precluding major surgery.

          3. Prior experimental therapy with novel agents

          4. Prior HIPEC

          5. History of brain metastases

          6. Childs B or C cirrhosis or with evidence of severe portal hypertension by history,
             endoscopy, or radiologic studies or with evidence of moderate to severe ascites.

          7. Weight less than 40 kg.

          8. History of congestive heart failure and/or an LVEF &lt; 40%

             Note: Patients at increased risk for coronary artery disease or cardiac dysfunction
             (e.g., &gt; 65yo, diabetes, history of hypertension, elevated LDL, first degree relative
             with coronary artery disease) will undergo full cardiac evaluation and will not be
             eligible if they demonstrate significant irreversible ischemia on stress thallium or
             an ejection fraction &lt; 40%. Patients may be eligible if cardiac status is treated and
             improves to within eligibility criteria.

          9. Significant COPD or other chronic pulmonary restrictive disease with PFT's indicating
             an FEV1 less than 50% or a DLCO less than 40% predicted for age.

             Note: Patients who have shortness of breath with minimal exertion or who are at risk
             for pulmonary disease (e.g., chronic smokers) will undergo pulmonary function testing.

         10. Discretion of principle investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989 Jan 15;63(2):364-7.</citation>
    <PMID>2910444</PMID>
  </reference>
  <reference>
    <citation>Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carten√¨ G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005 Aug 1;23(22):4866-75. Epub 2005 Jun 6.</citation>
    <PMID>15939922</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <verification_date>February 9, 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2010</study_first_submitted>
  <study_first_submitted_qc>March 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Colon Cancer</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>Peritoneal Perfusion</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

